Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 25 of 435 for:    colon cancer AND Capecitabine

A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01311050
Recruitment Status : Unknown
Verified December 2011 by King Faisal Specialist Hospital & Research Center.
Recruitment status was:  Recruiting
First Posted : March 9, 2011
Last Update Posted : December 13, 2011
Sponsor:
Information provided by (Responsible Party):
King Faisal Specialist Hospital & Research Center

Brief Summary:
A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

Condition or disease Intervention/treatment
Metastatic Colorectal Cancer Drug: Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab

Detailed Description:
A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

Layout table for study information
Study Type : Observational
Estimated Enrollment : 46 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer
Study Start Date : January 2009

Resource links provided by the National Library of Medicine



Intervention Details:
  • Drug: Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab
    Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   14 Years to 85 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Metastatic Colorectal Cancer
Criteria

Inclusion Criteria:

  • Patients with diagnosed Metastatic Colorectal Cancer

Exclusion Criteria:

  • Patients with diagnosis other than Metastatic Colorectal Cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01311050


Contacts
Layout table for location contacts
Contact: Shouki Bazarbashi, M.D. +966-1-4423949

Locations
Layout table for location information
Saudi Arabia
Kfsh & Rc Recruiting
Riyadh, Saudi Arabia
Sponsors and Collaborators
King Faisal Specialist Hospital & Research Center
Investigators
Layout table for investigator information
Principal Investigator: Shouki Bazarbashi, M.D. KFSH & RC

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier: NCT01311050     History of Changes
Other Study ID Numbers: RAC# 2081-068
RAC# 2081-068
First Posted: March 9, 2011    Key Record Dates
Last Update Posted: December 13, 2011
Last Verified: December 2011
Keywords provided by King Faisal Specialist Hospital & Research Center:
Metastatic Colorectal Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Colonic Diseases
Capecitabine
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Bevacizumab
Oxaliplatin
Irinotecan
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors